Takeda, Arthritis Foundation launch gout awareness effort

Share this article:
Takeda, Arthritis Foundation launch gout awareness effort
Takeda, Arthritis Foundation launch gout awareness effort

Takeda Pharmaceuticals North America and the Arthritis Foundation launched a gout awareness campaign featuring TV and radio PSAs airing nationally, along with a website, www.goutliving.org.

It's the first-ever high-profile education effort around the disease, said Takeda and the Arthritis Foundation, and it aims to communicate that “ living with the disease “doesn't have to mean missing out on life's special moments.”

The website includes an “attack tracker,” points for discussion with physicians, and a glossary of medical terms.

Takeda's Uloric won FDA approval for chronic management of hyperuricemia in patients with gout last year, becoming the first new gout drug to win approval in four decades.

The PSAs were produced by M Street Creative. PR is being handled by Ketchum.

Coincidentally, the campaign launched a day before Savient's gout drug Krystexxa (pegloticase) won FDA approval as a second-line treatment. Krystexxa has a different mechanism of action than xanthine oxidase inhibitors like Uloric, making it a potentially valuable treatment in patients for whom conventional treatments like the Takeda drug don't work. However, Krystexxa also carries a black box warning of possible severe allergic reaction experienced by a quarter of all patients in clinical trials.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.